-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Chronic hypertension: effect of blood pressure control on pregnancy outcome.
Panaitescu AM, Roberge S, Nicolaides KH.
J Matern Fetal Neonatal Med 2019;32:857-863. pdf -
Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A, Jabak S, De Castro H, Frei L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2019;54:79-86. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:755-61. pdf -
Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tayyar A, Krithinakis K, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:573-9. pdf -
Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:565-72. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:478-83. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf -
Maternal serum alpha-fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:466-71. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;35:249-57. pdf -
Association of placental volume measured by MRI and birth weight percentile.
Derwig IE, Akolekar R, Zelaya FO, Gowland PA, Barker GJ, Nicolaides KH.
J Magn Reson Imaging 2011;34:1125-30. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
Maternal cardiac function in normotensive and pre-eclamptic intrauterine growth restriction.
Bamfo JE, Kametas NA, Chambers JB, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:682-6. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
The role of uterine artery Doppler in predicting adverse pregnancy outcome.
Papageorghiou AT, Yu CK, Nicolaides KH.
Best Pract Res Clin Obstet Gynaecol 2004;18:383-96.